

AMERICAN THORACIC SOCIETY DOCUMENTS

**Official American Thoracic Society Clinical Practice Guidelines: Diagnostic Evaluation
of Infants with Recurrent or Persistent Wheezing**

Clement L. Ren*, Charles R. Esther, Jr.*, Jason Debley, Marianna Sockrider, Ozge Yilmaz, Nikhil Amin, Alia Bazzi-Asaad, Stephanie D. Davis, Manuel Durand, Jeffrey M. Ewig, Hasan Yuksel, Enrico Lombardi, Terry L. Noah, Peggy Radford, Sarath Ranganathan, Alejandro Teper, Miles Weinberger, Jan Brozek, and Kevin C. Wilson;
on behalf of

THIS OFFICIAL CLINICAL PRACTICE GUIDELINE OF THE AMERICAN THORACIC SOCIETY (ATS) WAS
APPROVED BY THE ATS BOARD OF DIRECTORS

*These authors contributed equally to this work.

Correspondence and requests for reprints should be addressed to Clement L. Ren, M.D., Indiana University School of Medicine, Riley Hospital for Children, 705 Riley Hospital Drive/ROC4270, Indianapolis, IN 46202. E-mail: clren@iu.edu

ABSTRACT

Background: Infantile wheezing is a common problem, but there are no guidelines for the evaluation of infants with recurrent or persistent wheezing that is not relieved or prevented by standard therapies.

Methods: An American Thoracic Society sanctioned guideline development committee selected clinical questions related to uncertainties or controversies in the diagnostic evaluation of wheezing infants. Members of the committee conducted pragmatic evidence syntheses, which followed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The evidence syntheses were used to inform the formulation and grading of recommendations.

Results: The pragmatic evidence syntheses identified few studies that addressed the clinical questions. The studies that were identified constituted very low quality evidence, consisting almost exclusively of case series with risk of selection bias, indirect patient populations, and imprecise estimates. The committee made conditional recommendations to perform bronchoscopic airway survey, bronchoalveolar lavage, esophageal pH monitoring, and a swallowing study. It also made conditional recommendations against empiric food avoidance, upper gastrointestinal radiography, and gastrointestinal scintigraphy. Finally, the committee recommended additional research about the roles of infant pulmonary function testing and food avoidance or dietary changes based on allergy testing.

Conclusions: Although infantile wheezing is very common, there is a paucity of evidence to guide clinicians in selecting diagnostic tests for recurrent or persistent wheezing. Our committee made several conditional recommendations to guide clinicians; however, additional research that measures clinical outcomes is needed to improve our confidence in the effects of various diagnostic interventions and allow advice to be provided with greater confidence.

CONTENTS

Overview

Introduction

Use of These Guidelines

Methods

Definition

Process

Results

Question 1: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo airway survey via flexible fiberoptic bronchoscopy?

Summary of evidence

Rationale

Recommendation 1

Question 2: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo a bronchoalveolar lavage?

Summary of evidence

Rationale

Recommendation 2

Question 3: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids be managed according to the results of infant pulmonary function testing using the raised-volume rapid thoracoabdominal compression (RVRTC) technique or clinical assessment alone?

Summary of evidence

Rationale

Recommendation 3

Question 4: Should infants without eczema who have persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo empiric food avoidance?

Summary of evidence

Rationale

Recommendation 4

Question 5: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo 24-hour esophageal pH monitoring?

Summary of evidence

Rationale

Recommendation 5

Question 6: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo an upper gastrointestinal series rather than 24-hour esophageal pH monitoring?

Summary of evidence

Rationale

Recommendation 6

Question 7: Should infants with persistent wheezing that is not relieved by bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo gastroesophageal scintigraphy rather than 24-hour esophageal pH monitoring?

Summary of evidence

Rationale

Recommendation 7

Question 8: Should infants without neurologic pathology with persistent wheezing that is not relieved by bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo a swallowing function study?

Summary of evidence

Rationale

Recommendation 8

Limitations and Future Directions

OVERVIEW

Wheezing occurs commonly during infancy (1). In most cases, wheezing episodes are mild and easily treated (2). However, some infants will develop persistent or recurrent wheezing, which is often severe (3). These infants are frequently referred to pediatric pulmonology specialists for further evaluation and treatment. Guidelines for diagnostic testing exist for older children with asthma (4), but such guidelines are lacking for wheezing infants. In a 2009 survey of Pediatrics Assembly members of the American Thoracic Society (ATS), infantile wheezing was one of the highest ranked topics for which members desired a guideline. To address this knowledge gap and interest, the ATS convened a committee of pediatric pulmonologists with clinical and research experience in infantile wheezing to develop evidence-based guidelines for the diagnostic evaluation of infantile wheezing.

For these guidelines, the committee defined infantile wheezing as recurrent or persistent episodes of wheezing in infants <24 months old (herein referred to as “infants with persistent wheezing”). The guidelines address diagnostic tests that are frequently considered by pediatric pulmonologists and other clinicians when evaluating infantile wheezing, but are either controversial or a frequent source of uncertainty. Diagnostic tests that are generally considered standard of care (e.g., chest radiography) were not addressed.

The committee performed a pragmatic evidence synthesis and then used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach (5) to formulate and grade the following recommendations:

1. For infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest an airway survey via flexible fiberoptic bronchoscopy (conditional recommendation, very low quality of evidence).

2. For infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest bronchoalveolar lavage (BAL) (conditional recommendation, very low quality of evidence).
3. We recommend research studies in infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, which compare clinical outcomes among those who are managed according to results from infant pulmonary function testing using the raised-volume rapid thoracoabdominal compression (RVRTC) method versus those who are managed according to clinical assessment alone.
4. A. For infants who do not have eczema but have persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest that clinicians and caregivers do **NOT** use empiric food avoidance or dietary changes (conditional recommendation, very low quality of evidence).

B. We recommend research studies that determine if food avoidance or dietary changes guided by food allergy testing improves clinical outcomes in infants who do not have eczema but have persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids.
5. For infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest 24-hour esophageal pH monitoring (conditional recommendation, very low quality of evidence).
6. For infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest 24-hour esophageal pH monitoring rather than upper gastrointestinal radiography (conditional recommendation, very low quality of evidence).

7. For infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest 24-hour esophageal pH monitoring rather than gastrointestinal scintigraphy (conditional recommendation, very low quality of evidence).
8. For infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest performing video-fluoroscopic swallowing studies (conditional recommendation, very low quality of evidence).

INTRODUCTION

Wheezing during infancy is a common clinical problem. In the Tucson Children's Respiratory Study, a longitudinal birth cohort study of healthy full-term infants, 34% of children had at least one episode of wheezing before age 3 years (1). In some infants, this is a sign of early onset asthma(6), whereas other infants may wheeze because of diminished airway function or innate immune responses (7, 8). For the majority of infants, these wheezing episodes are mild, episodic, and easily treated. However, some infants will develop severe recurrent or persistent wheezing. Guidelines for the evaluation and treatment of asthma in older children and the general approach to the evaluation of infantile wheezing have been published (4, 9), but no guidelines exist for the use of more specialized testing, such as flexible fiberoptic bronchoscopy, in the evaluation of infants with persistent wheezing. Recognizing the need for clinical guidance on the diagnostic evaluation of wheezing infants, the American Thoracic Society (ATS) convened a guideline development committee of pediatric specialists to conduct pragmatic evidence syntheses and then use the evidence syntheses as the basis for recommendations for the evaluation of persistent wheezing in infancy.

USE OF THESE GUIDELINES

These ATS guidelines are not meant to establish a standard of care. Rather, they represent an effort to summarize evidence and provide reasonable clinical recommendations based upon that evidence. Clinicians, patients, third-party payers, other stakeholders, and the courts should never view these recommendations as dictates. No guidelines or recommendations can take into account all of the often compelling unique individual clinical circumstances. Therefore, no one charged with evaluating clinicians' actions should attempt to apply the recommendations from these guidelines by rote or in a blanket fashion. These guidelines are not intended to be a comprehensive review of the evaluation of infantile wheezing, but rather to provide evidenced based recommendations for a set of specialized diagnostic tests frequently considered in the evaluation of this patient population. Clinicians will be able to use these recommendations when considering specific diagnostic tests for the evaluation of persistent wheezing. Recommendations for order or selection of diagnostic testing are beyond the scope of this document, and such decisions will vary depending upon the specific clinical situation and parent preferences.

METHODS

Definition

For these guidelines, the committee defined infantile wheezing as recurrent or persistent episodes of wheezing in infants <24 months old (herein, referred to as “infants with persistent wheezing”). This cutoff was chosen for two reasons: there have been previous documents addressing wheezing in preschool aged (3-5 years old) children (10) and wheezing on the basis of diminished airway function tends to improve by age 3 years (1). The population was further limited to infants with persistent wheezing despite

treatment with recommended first line therapies of bronchodilators, inhaled corticosteroids, or systemic corticosteroids (11).

Process

The co-chairs (CLR, CE) were confirmed by the ATS' Pediatric Assembly, Program Review Subcommittee, and Board of Directors. A guideline development committee was then composed that consisted of pediatric clinicians and researchers with expertise in the evaluation of wheezing during infancy. All members of the committee disclosed and were vetted for potential conflicts of interest according to the rules and procedures of the ATS. The committee then developed clinical questions using the PICO (patient, intervention, comparator, and outcomes) framework. Each question was the basis of a pragmatic evidence synthesis, which consisted of searching the Medline and CINAHL databases using pre-specified search criteria, selecting studies based upon pre-specified selection criteria, and appraising and summarizing the evidence using the GRADE approach. The evidence syntheses were used as the basis for the formulation of recommendations, which was based upon consideration of the balance of benefits versus harms and burdens, quality of evidence, patient preferences, and cost and resource use. The recommendations were graded using the GRADE approach. The specifics of the PICO framework, outcomes, and other methods are described in greater detail in the online supplement.

RESULTS

Question 1: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo airway survey via flexible fiberoptic bronchoscopy?

Summary of evidence. Our literature search did not identify any studies that compared wheezing infants undergoing airway survey via bronchoscopy with wheezing infants who did not undergo airway survey. Therefore, our recommendation is based upon ten case series that collectively included 1364 patients and reported that 452 of the 1364 patients (33%) who underwent airway survey for respiratory symptoms were found to have an anatomic abnormality known to cause wheezing (Table 1) (12-21). Lesions included tracheomalacia, bronchomalacia, tracheobronchomalacia, vascular rings, vascular slings, and airway compression by a vascular structure. No major complications were reported in any of the case series, with minor complications such as transient hypoxemia described in 5-10% of subjects.

Infants with wheezing due to tracheomalacia, bronchomalacia, or tracheobronchomalacia are typically managed with observation alone if wheezing is the only abnormality or the associated symptoms are mild because the vast majority of infants improve over time with conservative therapy (22). Infants with wheezing due to tracheomalacia, bronchomalacia, or tracheobronchomalacia occasionally require an intervention (e.g., positive airway pressure, surgery, or stenting) due to accompanying life-threatening airway obstruction, respiratory failure, recurrent pneumonias, or failure to thrive. Positive airway pressure immediately decreases respiratory distress, restores airway patency, and improves pulmonary function according to multiple small case series and case reports (23-30). Surgery (most commonly, aortopexy) relieves obstruction in virtually all patients with tracheomalacia, but is less effective in patients with tracheobronchomalacia or bronchomalacia according to small case series (31-37). This was illustrated by a case series in which 21 out of 21 patients (100%) had tracheomalacia corrected by aortopexy, but only 1 out of 4 patients (25%) with tracheobronchomalacia was corrected by aortopexy (31). Airway stenting has been used to improve airway obstruction

in infants (38-42), but complications including formation of granulation tissue, migration, or erosion occurred in 50% of cases and were potentially associated with death in 2 of 22 infants (39, 40) . Newer approaches include direct tracheobronchopexy (43)

In contrast, wheezing due to vascular rings, vascular slings, and airway compression by a vascular structure is unlikely to self-resolve and surgical correction is performed for symptomatic patients. According to seven case series, improvement in respiratory symptoms was seen 88-100% of patients and complete resolution was seen in more than 50% of patients. Recurrent laryngeal nerve injury was the most common surgical complication and occurred in less than 10% of patients. More serious complications such as aortoesophageal fistula, heart failure, or wound infection associated with mortality occurred in less than 5% of patients (44-50).

Taken together, the evidence indicates that an anatomic abnormality known to cause wheezing can be identified by airway survey in approximately 33% of patients with respiratory symptoms, and in the committee's clinical experience more than 90% of such patients will improve because either their condition is self-limited or surgery can correct the abnormality. Thus, about 30% of patients are likely to benefit from an airway survey, either through direct intervention (surgery) or by avoiding unnecessary tests and treatments for a benign, self-limited condition. Identification of airway malacia may also help in management of infants believed to have concomitant asthma, since beta agonists may adversely affect airway dynamics in these children (51). The committee has very low confidence (i.e., quality of evidence) in the accuracy of these estimated effects because the case series had probable selection bias and most series looked at infants who underwent bronchoscopy for respiratory symptoms, not specifically wheezing.

Rationale. Bronchoscopy with airway survey that identifies an anatomical cause of wheezing confers several potential benefits. Finding tracheomalacia, bronchomalacia, or tracheobronchomalacia usually leads to conservative management, which has a high success rate and other benefits including relief from the burden, cost, and potential harms of further diagnostic testing; probable reductions in the use of ineffective medications (bronchodilators or systemic corticosteroids) and the frequency of physician visits; and, parental reassurance given the high likelihood that the condition will spontaneously resolve. Finding vascular rings, vascular slings, and airway compression by a vascular structure leads to surgical therapy with an 88-100% success rate. In the judgment of the committee, the possibility that ~30% of infants who undergo airway survey will benefit far exceeds the burdens and cost of bronchoscopy, as well as the potential harms (i.e., complications due to bronchoscopy are rare and complications due to subsequent therapy range from zero for conservative management to approximately 10% for surgery). The recommendation for airway survey is conditional because the low quality of evidence provides little certainty that the benefits of airway survey exceed the burdens, costs, and harms. There are also emerging data on neurodevelopment risks to anesthesia that need to be considered (52). In addition, parental preferences regarding invasive procedures tend to be highly individualized.

Recommendation 1.

For infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest airway survey via flexible fiberoptic bronchoscopy (conditional recommendation, very low quality of evidence).

Question 2: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo a bronchoalveolar lavage?

Summary of evidence. Our literature search did not identify any studies that compared wheezing infants undergoing bronchoalveolar lavage (BAL) with wheezing infants who did not undergo BAL. Therefore, our recommendation is based upon data from 20 case series showing that 14 to 80% (40 to 60% in most studies) of infants with recurrent or persistent wheezing have a positive BAL culture according to 20 case series identified by our literature search (Table 2) (12, 16, 18, 53-70). No complications were reported in any of the case series.

Patients with a positive BAL culture typically receive a prolonged course of antibiotic therapy, and indirect evidence from a randomized trial of 50 children with productive cough presumed due to bacterial bronchitis found that cough resolved in 48% of children who received antibiotic therapy, compared with only 16% of those who did not receive antibiotics (71). The trial likely underestimated the effects of antibiotics in patients with bacterial bronchitis because children did not need to have a confirmed bacterial infection to be enrolled in the trial; patients without bacterial bronchitis are unlikely to have responded to antibiotic therapy and, therefore, their inclusion would have made antibiotic therapy appear less effective.

Based on the rates of BAL infection (40-60%) and symptom improvement with antibiotic treatment (48%) described above, we estimate that 20-30% of children with persistent wheezing who undergo bronchoscopy with BAL will be found to have a lower airway bacterial infection and their symptoms will improve with antibiotic therapy. The committee's confidence in the estimated effects of BAL (i.e., the quality of evidence) is very

low because it is based upon prevalence estimates derived from case series and a therapeutic effect estimated from a randomized trial, both of which had serious limitations. The case series were limited by selection bias, indirectness of the population (children with cough rather than infants with wheezing), and small samples sizes with few events. The randomized trial was similarly limited by indirectness of the population (children with cough rather than infants with wheezing), indirectness of the outcome (cure of infection rather than improvement in wheezing), and imprecision (small sample size with few events).

Rationale. To confirm or exclude lower airways bacterial infection as the cause of recurrent or persistent wheezing, clinicians have three options: 1) they can perform BAL and then treat patients with confirmed bacterial infection with antibiotics, 2) they can empirically treat all patients with empiric antibiotics, or 3) they can do neither. The committee judged the balance of the benefits versus the burdens and risks to be greater for the first option (i.e., 20 to 30% children improve after treatment of BAL identified infection) than either the second option (i.e., the same infection cure rate, but 40 to 60% of patients receive unnecessary antibiotics with their associated risks such as fever, rash, anaphylaxis, acquisition of resistance, and change in gut microbiome (72)) or third option (i.e., only 6.4 to 9.6% infection cure rate). The committee recognized that the estimated cure rates for lower respiratory infection likely overestimate the cure rate for wheezing because some infants with lower respiratory tract bacterial infection have additional or alternative causes for wheezing; nonetheless, the committee still thought that the risk of BAL is sufficiently small that the benefits probably outweigh the burdens and harms.

The strength of the recommendation for BAL is conditional because the committee's very low confidence in the estimated effects of BAL made it impossible to be certain that the

benefits of BAL outweigh the risks and burdens in the majority of patients. Moreover, BAL requires bronchoscopy, an invasive procedure requiring sedation, and it is uncertain that most families would want bronchoscopy performed on their infant, despite persistent wheezing.

Recommendation 2.

For infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest bronchoalveolar lavage (BAL) (conditional recommendation, very low quality of evidence).

Question 3: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids be managed according to the results of infant pulmonary function testing using the raised-volume rapid thoracoabdominal compression (RVRTC) technique or clinical assessment alone?

Summary of evidence. Our literature search revealed 1,261 studies related to wheezing and pulmonary function tests (PFTs) in children. The overwhelming majority (1,226 studies) were excluded because they enrolled children during later childhood and the guideline development committee felt that such evidence was too indirect to inform judgments for infants. Among the 35 studies that involved PFTs performed during infancy, only two (from the same cohort of patients at two different time points) described clinical outcomes following the assessment of bronchodilator responsiveness (BDR) using the RVRTC technique (73, 74). Both studies reported that the presence of BDR identified by the RVRTC technique predicted future acute exacerbations of wheezing requiring treatment with

systemic corticosteroids. No studies were identified that compared the effects of management according to the BDR measured by the RVRTC technique versus management based upon clinical assessment alone (i.e., no PFTs) on the clinical outcomes of interest (frequency of wheezing, frequency of doctor visits, frequency of hospitalization, prescriptions for bronchodilators, prescriptions for inhaled or systemic corticosteroids, parental stress, additional diagnostic testing, and inappropriate therapy). Thus, there was no published evidence available to inform the guideline development committee's judgments.

Rationale. In the absence of published evidence, the guideline development committee turned to its collective clinical experience to try to answer the question. However, despite extensive discussion, the guideline development committee could not reach consensus on a clinical recommendation for or against infant PFTs due to the paucity of evidence. Some members of the committee felt that the information derived from infant PFTs did not justify the burdens and risks involved in performing the test. Among the potential benefits of confirming or excluding a BDR, the clinician may be directed away or toward diagnostic testing that targets anatomical causes of wheezing, respectively. Among the risks and burdens of such testing are the need for sedation; the risks associated with airway occlusion, gastric distention, and aerophagia; the additional personnel needed to monitor the infant during and after the test; and time and personnel needed to set-up and conduct the test. Other members of the guideline development committee believed that there are circumstances in which infant PFTs are clinically useful. For example, a restrictive pattern on the PFT might lead clinicians to explore interstitial lung disease, while marked gas trapping might motivate clinicians to evaluate the infant further for neuroendocrine

hyperplasia of infancy, although wheezing is usually not a common feature of this condition (75).

Recommendation 3.

In infants with persistent wheezing **despite treatment with** bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we recommend research studies that compare clinical outcomes among infants who are managed according to infant pulmonary function testing performed using the RVRTC technique versus those who are managed according to clinical assessment alone.

Question 4: Should infants without eczema who have persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo empiric food avoidance?

Summary of evidence. The National Institute of Allergy and Infectious Disease has published clinical guidelines on food allergy in children with eczema, including recommendations for food allergy testing and avoidance in infants and children with this condition (76). Therefore, we focused our question on the role of food avoidance in infants without eczema. Our systematic review identified four studies that assessed the results of empiric food avoidance (Table 3). All of the studies measured our pre-specified outcome of frequency of wheezing, but none measured any of our other pre-specified outcomes, including frequency of doctor visits, frequency of hospitalization, prescriptions for bronchodilators, prescriptions for inhaled or systemic corticosteroids, parental stress, additional diagnostic testing, and inappropriate therapy. A trial randomly assigned 487 infants to receive either a cow's milk-free diet or a usual diet for at least the initial four

months of life and found no difference in wheezing, eczema, or nasal discharge at one year (77). Four hundred forty six of the infants were reassessed six years later. There were still no differences in the incidence of wheezing, asthma diagnoses, eczema, or allergic rhinitis (78). Another trial randomly assigned 110 infants to receive either a partially hydrolyzed formula or standard infant formula for the first four months of life. There was no difference in the incidence of wheezing at two years, although eczema was more common among the infants who received a standard formula (79). Finally, a prospective cohort study followed 6905 newborns through pre-school age and found no relationship between the early introduction of potentially allergenic foods (e.g. cow's milk, egg, nuts, soy, or gluten) and either wheezing or eczema at ages 2, 3, and 4 years. The study plans to follow the participants to adulthood (80). None of the studies evaluated the effects of empiric food avoidance in a subgroup of food antigen IgE-positive infants.

Taken together, the evidence suggests that empiric food avoidance has no effect on the frequency of wheezing. However, it provides very low confidence (i.e., quality of evidence) in the estimated effects because the randomized trials were limited by risk of bias, indirectness of population and intervention, and imprecision, and the observational study was limited by possible recall bias.

Rationale. The guideline development committee chose to include questions regarding food avoidance and allergy testing because in the collective experience of the committee, parents of infants with persistent wheezing frequently raise this topic. While there is evidence that respiratory symptoms can be provoked by food antigens in infants with eczema (81), less is known about this relationship in infants without eczema. The guideline development committee's judgments were based upon the impact of empiric food avoidance on frequency of wheezing, since our other pre-specified outcomes were not reported. The lack

of beneficial effects due to empiric food avoidance in any study, combined with the committee's recognition that empiric food avoidance can be burdensome, led the committee to suggest that empiric food avoidance not be used in infants without eczema who have persistent wheezing despite standard therapy. The strength of the recommendation is conditional because the very low quality of evidence prevented the committee from being certain about its judgments. In other words, while the committee believes that there is no evidence that the desirable consequences of empiric food avoidance outweighs the undesirable consequences in the majority of patients, it recognizes that there may be clinical circumstances in which a trial of empiric food avoidance may be reasonable for a minority of patients in which the clinical history strongly correlates respiratory symptoms with food exposure or respiratory symptoms are elicited in the double-blind placebo-controlled food challenge.

Recommendation 4.

- A. For infants without eczema who have persistent wheezing **despite treatment with** standard therapies, we suggest **NOT** using empiric food avoidance (conditional recommendation, very low quality of evidence).
- B. We recommend research to determine whether or not empiric food avoidance is beneficial for the subgroup of infants who are IgE-positive to food antigens.

Question 5: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo 24-hour esophageal pH monitoring?

Summary of evidence. Our systematic review did not identify any randomized trials or controlled observational studies that compared clinical outcomes among those who underwent 24-hour esophageal pH monitoring versus those who did not. However, we did identify three case series that used 24-hour pH monitoring to determine the prevalence of gastroesophageal reflux (GER) among children with wheezing and also reported the clinical outcomes that followed treatment of those with confirmed GER (Table 4) (82-84).

The most recent case series (83) enrolled 25 infants and children with asthma (88% had persistent wheezing) and performed 24-hour pH monitoring on all participants. GER was identified in 19 out of 25 (76%) infants and children. Participants with GER were treated with a proton pump inhibitor and reassessed at three months, at which time there were statistically significant improvements in symptoms (from 2.3 to 0.4 symptoms per day), use of bronchodilators (from 8.3 to 1.4 days per patient), use of systemic steroids (from 5.3 to 0.4 days per patient), frequency of exacerbations (from 1.5 to 0.3 exacerbations per patient), and hospitalizations (from 9.1 to 0.5 days per patient) compared with prior to treatment.

The case series confirmed three earlier series. In the first (82), 36 infants and children with various respiratory disorders underwent 24-hour pH monitoring. GER was identified in 22 out of 36 (61%) infants and children, including 4 out of 6 (67%) infants and children with wheezing. Among those 22 patients, nine patients underwent fundoplication, after which symptoms improved in six and resolved in three. The remaining 13 patients with GER were treated with medical management; nine had symptomatic improvement and four were lost to follow-up. In the second series (84), 12 infants with persistent wheezing despite bronchodilator and anti-inflammatory therapy underwent 24-hour pH monitoring and all were confirmed to have GER. They were subsequently treated with prokinetic agents and histamine receptor blockers; six improved enough to no longer require anti-asthma

medications, two improved enough that they only required intermittent anti-asthma medications, and four failed to improve and underwent fundoplication. Following fundoplication, three of the four patients no longer required anti-asthma medications. In the third series (85), 81 children with recurrent pneumonias or chronic asthma underwent 24-hour pH monitoring and 38 (47%) were found to have GER. Forty patients were treated for GER (two on the basis of alternative tests). Among the 12 children who underwent medical management, 10 improved (83%). Among the 24 children who underwent surgical treatment, 22 improved (92%). Four patients were lost to follow-up. None of the case series reported any adverse effects from the 24-hour pH monitoring or subsequent therapy.

Taken together, the evidence indicates that GER exists in 47% to 100% of infants with persistent wheezing and, if identified, more than 83% (most estimates are in the 90-100% range) will improve with medical or surgical treatment. However, the evidence provides very low confidence in the estimated effects. With respect to indirectness of the population, most studies included older children with a mix of respiratory problems in addition to wheezing (e.g., recurrent pneumonia, apnea, stridor, and cough) and did not evaluate the wheezing infant subgroup. With respect to indirectness of the intervention, there was variability in the methods used for 24-hour pH monitoring, including positioning of probes, patient positioning, dietary restrictions, scoring criteria, definitions of an abnormal study, and use of impedance data. pH probes detect only acid reflux unless paired with impedance; thus, not using impedance data may underestimate episodes of postprandial reflux in infants with frequent feeds and buffering of gastric contents (86).

Rationale. The guideline development committee felt that the balance of benefits versus risks, burdens, and cost favors 24-hour pH monitoring in most infants who have persistent wheezing despite bronchodilator and anti-inflammatory therapy. Specifically, among such

infants who undergo 24-hour pH monitoring, 67 to 100% will be found to have GER and nearly all will improve substantially with treatment, without requiring further diagnostic testing. The procedure is well tolerated by the vast majority of patients and while its semi-invasive nature and potential need for inpatient admission may be concerning to some parents, the committee felt that most families would be willing to have the test done. While combined pH and impedance probe monitoring has become the standard at most centers, the available evidence largely predates widespread use of impedance probes. Therefore, the committee was unable to comment specifically on the value of impedance monitoring.

An alternative to 24-hour pH monitoring is an empiric trial of anti-acid therapy. However, in up to one-third patients receiving empiric therapy, the anti-acid therapy is inappropriate and, incurs unnecessary cost, burden, and risk. In addition, the rate of treatment success is likely to be lower among empirically treated patients because those with GER that requires fundoplication may be incorrectly considered non-responders. In that case, it may be presumed that GER is not a contributor and the parents may never be offered potentially curative surgical therapy. Furthermore, recent studies in older patients suggest that proton pump inhibitor (PPI) therapy is linked to increased risk of pneumonia (87). While a similar risk has not been reported in infants, a normal pH monitoring study could potentially reduce any risks associated with PPI therapy.

The strength of our recommendation is conditional because the very low quality of evidence provided little confidence in the estimated benefits and harms reported by the case series. As a result, the committee could not be certain about its judgments regarding the balance of benefits versus harms, burdens, and cost.

Recommendation 5.

For infants with persistent wheezing that is not relieved by bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest 24-hour esophageal pH monitoring (conditional recommendation, very low quality of evidence).

Question 6: Should infants with persistent wheezing despite treatment with bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo an upper gastrointestinal series rather than 24-hour esophageal pH monitoring?

Summary of evidence. The guideline development committee next asked whether an upper gastrointestinal (UGI) series is an acceptable alternative to 24-hour esophageal pH monitoring, which we considered the reference standard. Our systematic review did not identify any randomized trials or controlled observational studies that compared clinical outcomes among those who underwent an UGI series with those who underwent 24-hour esophageal pH monitoring. However, it did identify three studies that evaluated the accuracy of UGI series in detecting GER in infants and children with wheezing (Table 4) (82, 85, 88).

In the only study that used 24-hour pH monitoring as the reference standard, 79 children (ages 2 to 17 years) who had difficult-to-control asthma underwent 24-hour esophageal pH monitoring. GER was identified in 58 out of 79 (73%) children. A barium swallow study was then performed, which identified GER with a sensitivity and specificity of 46% and 82%, respectively (88).

The other two studies used varying reference standards, but reported enough data to enable us to estimate the sensitivity of UGI series in the detection of GER relative to 24-hour esophageal monitoring. In a study of infants and children (age 2 months to 10.5 years) with recurrent respiratory disorders (82), 22 out of 36 (61%) were found to have GER by 24-

hour pH monitoring and 15 out of 35 (42%) were found to have GER by UGI series. Assuming that patients in whom GER was detected by UGI series also had GER detected by 24-hour pH monitoring, the sensitivity of UGI series would be 68%. In a study of 82 infants and children (5 months to 16 years) with recurrent pneumonia or chronic asthma (85), 40 were found to have GER based on study criteria of whom 30/40 had positive UGI series and 38/39 had positive 24-hour pH monitoring studies (one patient did not have pH monitoring). Based on these numbers, the sensitivity of UGI series would be 75%, compared to 97% for pH probe. The sensitivity of UGI series appears to be similarly poor among children without respiratory symptoms (89).

These accuracy tests constitute very low quality evidence, meaning that they provide very low confidence in their results. The poor quality of evidence reflects the fact that the studies did not enroll consecutive patients and it was not reported whether there was legitimate uncertainty about the presence or absence of GER.

Rationale. The primary advantages of performing an UGI series rather than 24-hour esophageal pH monitoring are that an UGI series can be performed less invasively and in a shorter duration. A less frequent advantage is that UGI series occasionally demonstrate pertinent anatomical abnormalities, such as hiatal hernias or esophageal indentation suggestive of a vascular ring. The disadvantages of an UGI series are radiation exposure, the need for patient cooperation, and its semi-invasive nature.

The guideline development committee made the a priori decision that the benefits of UGI series would outweigh both the disadvantages of UGI series and the consequences of incorrect results if the false-negative rate were less than 10% (i.e., sensitivity greater than 90%) and the false-positive rate was less than 10% (i.e., specificity greater than 90%). In other words, assuming a prevalence of GER of roughly 60%, the committee would accept 40

false-positive results and 60 false-negative results for every 1000 patients tested. The acceptable false-negative and false-positive rates are both relatively small because 24-hour pH monitoring is not overly risky or burdensome.

The evidence indicates that the sensitivity (68-79%) and specificity (82%) of UGI series are insufficient to warrant the use of UGI series as an alternative to 24-hour esophageal pH monitoring. The recommendation against UGI series is conditional because the very low quality of evidence does not provide sufficient confidence in the estimated sensitivity and specificity to be certain that UGI series is not a worthwhile alternative. The meaning of a conditional recommendation is that it is right for most patients, but may not be right for a sizable minority in certain situations. As an example, an UGI series can be a valuable tool for identifying vascular rings or slings and may be considered if such malformations are suspected. An UGI series can also be considered in circumstances in which 24-hour pH monitoring is not a practical option.

Recommendation 6.

For infants with persistent wheezing that is not relieved by bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest 24-hour esophageal pH monitoring rather than upper gastrointestinal series (conditional recommendation, very low quality evidence).

Question 7: Should infants with persistent wheezing that is not relieved by bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo gastroesophageal scintigraphy rather than 24-hour esophageal pH monitoring?

Summary of evidence. The guideline development committee next asked whether gastroesophageal scintigraphy is an acceptable alternative to 24-hour pH monitoring, which we considered the reference standard. Our systematic review did not identify any randomized trials or controlled observational studies that compared clinical outcomes among those who underwent scintigraphy with those who underwent 24-hour esophageal pH monitoring. However, it did identify four studies that evaluated gastroesophageal scintigraphic detection of GER in infants and children with wheezing.

In the only study that used 24-hour pH monitoring as the reference standard, 79 children (ages 2 to 17 years) who had difficult-to-control asthma underwent 24-hour esophageal pH monitoring. Gastroesophageal scintigraphy identified GER with a sensitivity and specificity of 15% and 73%, respectively (88). Another study of infants with wheezing used clinical history and a response to anti-GER therapy as the reference standard instead of 24-hour pH monitoring. It found that gastroesophageal scintigraphy detected GER with a sensitivity and specificity of 58% and 85%, respectively, when a history compatible with GER was used as the reference standard and with a sensitivity and specificity of 79% and 50%, respectively, when a response to anti-GER therapy was used as the reference standard (90). Finally, two studies did not compare gastroesophageal scintigraphy to a reference standard, but rather, reported that the technique identified GER in 22% of infants and children (age 3 months to 4 years) who presented with recurrent wheezing or vomiting (91) and in 26% of infants and children (age 6 months to 6 years) who presented with difficult-to-treat asthma (92); these yields were lower than the 67-100% described above for 24-hour esophageal pH monitoring. The sensitivity of gastroesophageal scintigraphy appears to be similarly poor among infants and children without respiratory symptoms (89).

These accuracy studies constitute very low quality evidence, meaning that they provide very low confidence in their estimated effects. The poor quality of evidence reflects the fact that the studies did not enroll consecutive patients and it was not reported whether there was legitimate uncertainty about the presence or absence of GER. Moreover, there was indirectness of the population since our focus was on wheezing infants but many of the studies enrolled older children.

Rationale. The primary advantages of gastroesophageal scintigraphy rather than 24-hour esophageal pH monitoring are that scintigraphy can be performed less invasively and in a shorter duration. The disadvantages of scintigraphy are primarily radiation exposure (albeit less than that required for UGI series) and high cost.

The guideline development committee made an a priori decision that the advantages of gastroesophageal scintigraphy would outweigh the disadvantages associated with potential incorrect results if the false-negative rate were less than 10% (i.e., sensitivity greater than 90%) and the false-positive rate is less than 10% (i.e., specificity greater than 90%). In other words, assuming a prevalence of GER of roughly 60%, the committee would accept 40 false-positive results and 60 false-negative results for every 1000 patients tested. The acceptable false-negative and false-positive rates are both relatively small because 24-hour pH monitoring is not overly risky or burdensome.

The evidence indicates that the sensitivity and specificity (15% and 73%, respectively) of gastroesophageal scintigraphy are insufficient to warrant the use of scintigraphy as an alternative to 24-hour esophageal pH monitoring. The recommendation against scintigraphy is conditional because the very low quality of evidence does not provide sufficient confidence in the estimated sensitivity and specificity to be certain that scintigraphy is not a worthwhile alternative.

Recommendation 7.

For infants with persistent wheezing that is not relieved by bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest 24-hour esophageal pH monitoring rather than gastrointestinal scintigraphy (conditional recommendation, very low quality evidence).

Question 8: Should infants without neurologic pathology with persistent wheezing that is not relieved by bronchodilators, inhaled corticosteroids, or systemic corticosteroids undergo a swallowing function study?

Summary of evidence. Our literature review did not identify any randomized trials or controlled observational studies that compared clinical outcomes among those who underwent a swallowing function study versus those who did not. However, it did identify two case series that reported the prevalence of aspiration detected by video-fluoroscopic swallowing function studies in infants and children who did not have chronic illnesses but did have respiratory symptoms including wheezing (Table 5). Both series also reported the outcomes of treatment (93, 94).

The first series enrolled 472 infants (age less than one year) with either respiratory symptoms or vomiting and performed fluoroscopic swallowing studies on each. Swallowing dysfunction was detected in 63 out of 472 (13%) infants. Among these infants, 70% had tracheal aspiration and 30% had laryngeal penetration. Since the coordination of swallowing improves with age among infants without chronic illnesses, the infants with swallowing dysfunction were managed by thickening the consistency of their food. Tracheal

aspiration or laryngeal penetration was seen in 179 swallowing studies with thin liquids, 61 studies with thickened liquids, and 14 studies with pureed food(93).

The second case series included 112 infants (age less than one year) with wheezing or intermittent stridor and performed video-fluoroscopic swallowing function studies on each. Swallowing dysfunction was detected in 13 out of 112 (12%) infants. Nine infants were treated with a thickened diet, while four infants had their oral feedings stopped and received nasojejunal or gastrostomy feedings temporarily. In all of the infants, the swallowing dysfunction resolved within 3-9 months (94).

Taken together, the evidence suggests that swallowing dysfunction, which is known to cause wheezing, can be identified by video-fluoroscopic swallowing studies in 10-15% of infants who do not have a chronic illness but have respiratory symptoms. More than 90% of such patients will improve with feeding interventions while waiting for the swallowing coordination to improve with age. Thus, 9-14% of patients who undergo video-fluoroscopic swallowing studies may derive some benefit. The committee has very low confidence (i.e., quality of evidence) in the accuracy of these estimated effects because the study designs were case series (i.e., they were uncontrolled); and there was risk for indirectness (i.e., most series looked at infants who had a variety of respiratory symptoms, not specifically wheezing).

Rationale. A video-fluoroscopic swallowing study confers several potential benefits.

Finding swallowing dysfunction usually leads to feeding modifications that reduce aspiration by approximately 90%; a reduction in aspiration is a surrogate outcome for persistent wheezing, stridor, cough, and pneumonia. Other benefits include relief from the burden, cost, and potential harms of further diagnostic testing; probable reductions in the use of ineffective medications (bronchodilators or inhaled corticosteroids) and the

frequency of physician visits; and, parental reassurance given the high likelihood that the condition will spontaneously resolve. Limitations include the need for infant/child cooperation, cost, availability of speech pathologist, and the risk of aspiration during the study. The committee judged that the desirable consequences outweigh the undesirable consequences and, therefore, suggests that infants with persistent wheezing that has not responded to conventional therapies undergo a video-fluoroscopic swallowing study. The recommendation is conditional because the very low quality of evidence provides little certainty that the benefits of a video-fluoroscopic swallowing study exceed the burdens, costs, and harms.

Recommendation 8.

For infants without neurologic pathology with persistent wheezing that is not relieved by bronchodilators, inhaled corticosteroids, or systemic corticosteroids, we suggest a swallowing function study to evaluate for aspiration (weak recommendation, very low quality of evidence).

LIMITATIONS AND FUTURE DIRECTIONS

A common theme throughout our guidelines development was the striking paucity of data regarding infantile wheezing. Despite the how widespread and common this clinical problem is, we were unable to find any large clinical studies that utilized consistent case definitions and outcomes. Most all of the studies cited were case series, the lowest quality of evidence on the GRADE scale. Given the frequency with which infantile wheezing occurs, there is an urgent need for more rigorous research to be conducted in this field.

Although we utilized the GRADE methodology, we rarely had patient important outcomes that could be reliably linked to performance of the various diagnostic tests. As a

result, we presumed that treatment strategies based on a positive test would provide therapeutic benefit to the patient, but this presumption and limited evidence reduced our ability to make strong recommendations.

One clear need for future research is to determine whether implementation of these tests actually leads to treatment that improves patient important outcomes. Outcome measures should include both clinical responses and parental preferences, particularly with regards to choices between diagnostic testing and empiric treatment. However, study design is complicated by the fact that a substantial fraction of infants with persistent wheeze not responsive to standard therapies have anatomic abnormalities that may not respond to any medical therapy. Routine incorporation of bronchoscopy into clinical trials could address this issue, but likely would be problematic given the relatively high costs and risks associated with this procedure.

This issue highlights the fact that many current tests involve substantial costs and/or risks that limit widespread utilization. Further research should address whether diagnosis could be achieved using less invasive tests radiologic studies *in lieu* of bronchoscopy for anatomic abnormalities, or analysis of exhaled breath to detect markers of airway infection or reflux. Comparative effectiveness studies and the development of clinical pathways would also help clinicians better evaluate infants with persistent wheezing.

In summary, this document provides guidelines that further two goals of interest to the ATS. First, they will aid the pediatric generalist or respiratory specialist in the management of the infant with recurrent or persistent wheeze that does not respond to conventional therapies. Second, they will serve to identify the research needed to improve diagnosis and treatment of this vulnerable population.

This clinical practice guideline was prepared by an *ad hoc* subcommittee of the

Members of the subcommittee are as follows:

CLEMENT L. REN, M.D. (*Co-Chair*)

CHARLES R. ESTHER, JR., M.D., PH.D. (*Co-Chair*)

JASON DEBLEY, M.D., M.P.H.

MARIANNA SOCKRIDER, M.D., M.P.H., D.P.H.

OZGE YILMAZ **[AU: Please provide degree for this author.]**

NIKHIL AMIN, M.D.

ALIA BAZZY-ASAAD, M.D.

STEPHANIE D. DAVIS, M.D.

MANUEL DURAND, M.D.

JEFFREY M. EWIG, M.D.

HASAN YUKSEL, M.D.

ENRICO LOMBARDI, M.D.

TERRY L. NOAH, M.D.

PEGGY RADFORD, M.D.

SARATH RANGANATHAN, M.D.

ALEJANDRO TEPPER, M.D.

MILES WEINBERGER, M.D.

JAN BROZEK, M.D., PH.D.

KEVIN C. WILSON, M.D.

Author Disclosures: TK

Table 1: Airway Survey - Quality Assessment and Summary of Findings Table

Quality Assessment									Summary of findings
Number (N)	Study Design	Limitations	Indirectness	Inconsistency	Imprecision	Publication Bias	Importance of Outcome	Quality of evidence	
Frequency with which bronchoscopy identifies an anatomical lesion known to cause wheezing									
10 ¹	Case series ²	Serious ³	Serious ⁴	None	Serious ⁵	Undetected	Not a pre-specified outcome	Very low	The ten case series collectively included 1364 patients. 452/1364 (33%) patients were found to have anatomical abnormalities known to cause wheezing. The largest series included 885 patients. When this study was removed, the estimate was unchanged. Complications were rarely reported.
Frequency of wheezing post-treatment									
27 ⁶	Case series ² and case reports	Serious ⁷	Serious ⁸	None	Serious ⁹	Undetected	Critical	Very low	90% of patients with tracheomalacia, bronchomalacia, or tracheobronchomalacia, improved with time alone. 88-100% of patients with vascular rings, vascular slings, or vascular compression of the airways improved with surgery. Complications occurred in 10% and mortality in <5%.

Footnotes:
¹References (12-21)

²No studies included a control group. Therefore, they are all case series.

³Limitations were serious because of probable selection bias related to who had bronchoscopy performed and who did not. Most studies did not provide details of how they decided upon whom to perform bronchoscopy with airway survey and whom not to perform bronchoscopy with airway survey.

⁴Indirectness was serious because few studies were limited to just wheezing infants. Most included infants with respiratory symptoms or signs, such as stridor, wheezing, cough, respiratory distress or failure, or recurrent infections.

⁵Imprecision was serious because sample size was small (<100 or even smaller) in all but one of the studies that were reviewed.

⁶References (23-42, 44-50).

⁷Limitations were serious because of probable selection bias related to who was eventually treated with positive airway pressure, airway stenting, and surgery, as well as which type of surgery was used.

⁸Indirectness was serious because few studies were limited to just wheezing infants. Most included infants being treated for a variety respiratory symptoms or signs (e.g., stridor, wheezing, cough, respiratory distress or failure, or recurrent infections) caused by anatomical abnormalities.

.

Table 2: Bronchoalveolar Lavage - Quality Assessment and Summary of Findings Table

Quality Assessment									Summary of findings
Number (N)	Study Design	Limitations	Indirectness	Inconsistency	Imprecision	Publication Bias	Importance of Outcome	Quality of evidence	
Frequency with which BAL detects infection (defined as a positive culture)									
20 ¹	Case series ²	Serious ³	Serious ⁴	None ⁵	Serious ⁶	Undetected	Not a pre-specified outcome	Very low	Among the 20 case series identified, the proportion of BAL that resulted in a positive microbiological culture ranged from 14% to 80%; however, most series reported that 40 to 60% of BAL resulted in a positive microbiological culture. None of the series reported complications from BAL.
Frequency of wheezing post-treatment									
1 ⁷	RCT	Serious ⁸	Serious ⁹	None	Serious ⁶	Undetected	Critical	Very low	50 children with wet cough due to presumed bacterial bronchitis were treated with either antibiotics or no antibiotics. Among the patients who were treated, the cure rate was 48%. Among the patients who were not treated, the cure rate was 16%.

Footnotes:

¹References 6, 10, 12, 44-61.

²No studies included a control group. Therefore, they are all case series.

³Limitations were serious because of probable selection bias related to who had BAL performed and who did not. Most studies did not provide details of how they decided upon whom to perform bronchoscopy with BAL and whom not to perform bronchoscopy with BAL.

⁴Indirectness was serious because few studies were limited to just wheezing infants. Most included older children and frequently cough overlapped with wheezing.

⁵Inconsistency wasn't a problem. In most studies, the prevalence of positive BAL cultures was 40-60%.

⁶Imprecision was serious because sample size was small (<100 or even smaller) in all the studies that were reviewed.

⁷Reference (71).

⁸Descriptions of the concealment of allocation and blinding of the assessors was incomplete.

⁹Indirectness was serious because the population of interest is wheezing infants, but the population studied was children with cough. In addition, the outcome of interest was wheezing, but the outcome of the studies was cure of infection.

Table 3: Empiric Food Avoidance - Quality Assessment and Summary of Findings Table

Quality Assessment									Summary of Findings
Number (N)	Study Design	Limitations	Indirectness	Inconsistency	Imprecision	Publication Bias	Importance of Outcome	Quality of evidence	
Incidence of wheezing (measured at 1 year)									
1	RCT ¹	Serious ²	Serious ³	None	Serious ⁴	None	Critical	Very low	The trial of 487 infants found no difference in the incidence of wheezing during the first year of life: 84/232 (36%) vs. 80/242 (33%).
Incidence of wheezing (measured at >1 – 4 years)									
2	1 RCT ⁵ + 1 Observational study ⁶	Serious ⁷	Serious ⁸	None	Serious ⁴	None	Critical	Very low	The randomized trial of 110 infants found no difference in the incidence of wheezing at 2 years. The prospective cohort study of 6905 children found no difference in the incidence of wheezing at 2, 3, or 4 years among those who were introduced to cow’s milk, nuts, egg, soy, or gluten earlier or later than six months.
Incidence of wheezing (measured at >4 years)									
1	RCT ⁹	Serious ¹⁰	Serious ³	None	Serious ⁴	None	Critical	Very low	The trial of 446 infants found no

									difference in the incidence of wheezing during the initial seven years of life: 148/215 (69%) vs. 157/231 (68%).
Diagnosis of asthma									
1	RCT ⁹	Serious ¹⁰	Serious ³	None	Serious ⁴	None	Important	Very low	The trial of 446 infants found no difference in the incidence of asthma diagnoses during the initial seven years of life: 60/215 (28%) vs. 81/231 (35%).

Footnotes:¹Reference (77).²Concealment was by envelopes containing color coded cards and the caregivers were not blinded.³The question is about infants without eczema who have refractory wheezing; however, the trial enrolled newborns. In addition, the question asks about general food avoidance, but the trial employed only cow's milk avoidance.⁴The opposite ends of the confidence interval would result in different clinical decisions if real.⁵Reference (78)⁶Reference (79)⁷The randomized trial did not report concealment and the caregivers were not blinded; the observational study relied upon questionnaires that retrospectively assessed the introduction of certain foods into the diet, creating a risk of recall bias.⁸The question is for infants without eczema who have refractory wheezing; however, the randomized trial enrolled newborns with a family history of atopy and the observational study followed any newborn. In addition, the question asks about general food avoidance, but the trial employed only cow's milk avoidance.⁹Reference (80).¹⁰This was a 7-year follow-up of Miskelly, et al (77). Thus, it had the same limitations: Concealment was by envelopes containing color coded cards and the caregivers were not blinded. In addition, 41 of the 487 patients dropped out of the study between the first and seventh years.

Table 4: Gastroesophageal reflux - Quality Assessment and Summary of Findings Table

Quality Assessment									Summary of Findings
Number (N)	Study Design	Limitations	Indirect -ness	Inconsistency	Imprecision	Publicatio n Bias	Importance of Outcome	Quality of Evidence	
Frequency with which 24-hour esophageal pH monitoring (gold standard) identifies GER									
4	Case series ¹	Serious ²	Serious ³	None	Serious ⁴	None	Not a pre-specified outcome	Very low	24-hour esophageal pH monitoring identified GER in 19 out of 25 (76%) infants and children ⁵ , 22 out of 36 (61%) infants and children ⁶ , 12 out of 12 (100%) infants ⁷ , and 38 out of 81 (47%) children ⁸ .
Wheezing									
4	Case series ¹	Serious ²	Serious ³	None	Serious ⁴	None	Critical	Very low	A case series of 25 infants and children with presumed asthma found GER in 19/25 (76%). Following treatment of the GER, symptoms decreased from 2.3 to 0.4 symptoms per day and exacerbations decreased from 1.5 to 0.3 exacerbations per patient⁵. A case series of 36 infants and children with recurrent respiratory symptoms found GER in 22/36 (61%). Among those with GER, 9/22 (41%) underwent fundoplication with subsequent improvement or resolution in all, and 13/22 (59%) were medically managed with improvement in the nine who were not lost to follow-up⁶. A case series of 12 infants with persistent wheezing found GER

									in 12/12 (100%); following treatment of the GER, 6/12 (50%) no longer needed medications for wheezing, 2/12 (17%) needed medications only intermittently, and 4/12 (33%) needed fundoplication, which eliminated the need for medications in $\frac{3}{4}$ (75%)⁷. A case series of 81 children with recurrent pneumonias or chronic asthma found GER in 38/81 (47%). Forty patients were treated for GER (two on the basis of alternative tests). Among the 12 children who underwent medical management, 10 improved (83%). Among the 24 children who underwent surgical treatment, 22 improved (92%). Four patients were lost to follow-up⁸.
Use of bronchodilators									
1	Case series ⁵	Serious ²	Serious ⁹	None	Serious ¹⁰	None	Important	Very low	A case series of 25 infants and children with presumed asthma found GER in 19/25 (76%). Following treatment of the GER, use of bronchodilators decreased from 8.3 to 1.4 days per patient⁵.
Use of systemic steroids									
1	Case series ⁵	Serious ²	Serious ⁹	None	Serious ¹⁰	None	Important	Very low	A case series of 25 infants and children with presumed asthma found GER in 19/25 (76%). Following treatment of the GER, use of bronchodilators decreased from 5.3 to 0.3 days per patient⁵.
Hospitalizations									
1	Case series ⁵	Serious ²	Serious ⁹	None	Serious ¹⁰	None	Important	Very low	A case series of 25 infants and children with presumed asthma

									found GER in 19/25 (76%). Following treatment of the GER, use of bronchodilators decreased from 9.1 to 0.5 days per patient ⁵ .
--	--	--	--	--	--	--	--	--	---

Footnotes:

- ¹ References (82-85)
- ² There was no process to ensure that patients were consecutively or randomly included; thus, selection bias in favor of infants clinically suspected of having GER is likely.
- ³ The question is specifically about infants with wheezing; however, three of the case series included older children and symptoms other than wheezing.
- ⁴ There were only 154 patients in the four case series combined.
- ⁵ Reference (83)
- ⁶ Reference (84)
- ⁷ Reference (82)
- ⁸ Reference (85)
- ⁹ The question is specifically about infants with wheezing; however, the case series included older children and asthma symptoms other than wheezing.
- ¹⁰ The case series included only 25 infants and children, of which only 19 were treated for GER.

Table 5: Aspiration - Quality Assessment and Summary of Findings Table

Quality Assessment									Summary of Findings
Number (N)	Study Design	Limitations	Indirect -ness	Inconsistency	Imprecision	Publication Bias	Importance of Outcome	Quality of Evidence	
Frequency with which video-fluoroscopic swallowing studies (gold standard) identify aspiration due to swallowing dysfunction									
2	Case series ¹	Serious ²	Serious ³	None	Serious ⁴	None	Not a pre-specified outcome	Very low	472 infants (age less than one year) with either respiratory symptoms or vomiting underwent fluoroscopic swallowing studies; swallowing dysfunction was detected in 63 out of 472 (13%) infants⁵. 122 infants (age less than one year) with either wheezing or intermittent stridor underwent fluoroscopic swallowing studies; swallowing dysfunction was detected in 13 out of 112 (12%) infants⁶.
Wheezing (assessed by the surrogate outcome of radiographic tracheal aspiration or laryngeal penetration)									
2	Case series ¹	Serious ²	Serious ³	None	Serious ⁴	None	Critical	Very low	In a case series of 472 infants (age less than one year) with either respiratory symptoms or vomiting, tracheal aspiration or laryngeal penetration was seen in 179 swallowing studies with thin liquids, 61 studies with thickened liquids, and 14 studies with pureed food, a risk reduction of more than 90%⁵. In a case series of 122 infants (age less than one year) with either wheezing or intermittent stridor, nine infants with confirmed swallowing

									dysfunction were treated with a thickened diet, while four infants had their oral feedings stopped and received nasojunal or gastrostomy feedings temporarily. In all of the infants, the swallowing dysfunction resolved within 3-9 months ⁶ .
--	--	--	--	--	--	--	--	--	--

Footnotes:

¹Mercado-Deane M, et al. Pediatr Radiol 2001; 31:423-428 and Sheikh S, et al. Chest 2001; 120:1190-1195. References (93) and (94)

²There was no process to ensure that patients were consecutively or randomly included; thus, selection bias in favor of infants clinically suspected of having swallowing dysfunction is likely.

³The question is specifically about infants with wheezing; however, both case series included infants with symptoms other than wheezing.

⁴There were only 584 patients in the two case series combined.

⁵ Reference (93)

⁶ Reference (94)

References

1. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The group health medical associates. *N Engl J Med* 1995;332:133-138.
2. Devulapalli CS, Carlsen KC, Haland G, Munthe-Kaas MC, Pettersen M, Mowinckel P, Carlsen KH. Severity of obstructive airways disease by age 2 years predicts asthma at 10 years of age. *Thorax* 2008;63:8-13.
3. Bacharier LB, Phillips BR, Bloomberg GR, Zeiger RS, Paul IM, Krawiec M, Guilbert T, Chinchilli VM, Strunk RC, Childhood Asthma R, Education Network NHL, Blood I. Severe intermittent wheezing in preschool children: A distinct phenotype. *J Allergy Clin Immunol* 2007;119:604-610.
4. National Asthma E, Prevention P. Expert panel report 3 (epr-3): Guidelines for the diagnosis and management of asthma-summary report 2007. *J Allergy Clin Immunol* 2007;120:S94-138.
5. Schunemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, Fahy BF, Gould MK, Horan KL, Krishnan JA, Manthous CA, Maurer JR, McNicholas WT, Oxman AD, Rubenfeld G, Turino GM, Guyatt G, Development ATSD, Implementation C. An official ats statement: Grading the quality of evidence and strength of recommendations in ats guidelines and recommendations. *American journal of respiratory and critical care medicine* 2006;174:605-614.
6. Skoner D, Caliguiri L. The wheezing infant. *Pediatr Clin North Am* 1988;35:1011-1030.
7. Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. *N Engl J Med* 1988;319:1112-1117.
8. Guerra S, Lohman IC, Halonen M, Martinez FD, Wright AL. Reduced interferon γ production and soluble cd14 levels in early life predict recurrent wheezing by 1 year of age. *American journal of respiratory and critical care medicine* 2004;169:70-76.
9. Nelson textbook of pediatrics. In: Kliegman RM, editor, Edition 20. ed. Philadelphia, Pennsylvania :: Elsevier; 2016.
10. Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, de Blic J, de Jongste JC, Eber E, Everard ML, Frey U, Gappa M, Garcia-Marcos L, Grigg J, Lenney W, Le Souef P, McKenzie S, Merkus PJ, Midulla F, Paton JY, Piacentini G, Pohunek P, Rossi GA, Seddon P, Silverman M, Sly PD, Stick S, Valiulis A, van Aalderen WM, Wildhaber JH, Wennergren G, Wilson N, Zivkovic Z, Bush A. Definition, assessment and treatment of wheezing disorders in preschool children: An evidence-based approach. *Eur Respir J* 2008;32:1096-1110.
11. Ducharme FM, Tse SM, Chauhan B. Diagnosis, management, and prognosis of preschool wheeze. *Lancet* 2014;383:1593-1604.
12. Aslan AT, Kiper N, Dogru D, Karagoz AH, Ozcelik U, Yalcin E. Diagnostic value of flexible bronchoscopy in children with persistent and recurrent wheezing. *Allergy and asthma proceedings : the official journal of regional and state allergy societies* 2005;26:483-486.

13. Baraldi E, Donega S, Carraro S, Farina M, Barbato A, Cutrone C. Tracheobronchomalacia in wheezing young children poorly responsive to asthma therapy. *Allergy* 2010;65:1064-1065.
14. Cakir E, Ersu RH, Uyan ZS, Oktem S, Karadag B, Yapar O, Pamukcu O, Karakoc F, Dagli E. Flexible bronchoscopy as a valuable tool in the evaluation of persistent wheezing in children. *International journal of pediatric otorhinolaryngology* 2009;73:1666-1668.
15. Hauk PJ, Krawiec M, Murphy J, Boguniewicz J, Schiltz A, Goleva E, Liu AH, Leung DY. Neutrophilic airway inflammation and association with bacterial lipopolysaccharide in children with asthma and wheezing. *Pediatric pulmonology* 2008;43:916-923.
16. Le Bourgeois M, Goncalves M, Le Clainche L, Benoist MR, Fournet JC, Scheinmann P, de Blic J. Bronchoalveolar cells in children < 3 years old with severe recurrent wheezing. *Chest* 2002;122:791-797.
17. Masters IB, Chang AB, Patterson L, Wainwright C, Buntain H, Dean BW, Francis PW. Series of laryngomalacia, tracheomalacia, and bronchomalacia disorders and their associations with other conditions in children. *Pediatric pulmonology* 2002;34:189-195.
18. Saglani S, Nicholson AG, Scallan M, Balfour-Lynn I, Rosenthal M, Payne DN, Bush A. Investigation of young children with severe recurrent wheeze: Any clinical benefit? *Eur Respir J* 2006;27:29-35.
19. Saito J, Harris WT, Gelfond J, Noah TL, Leigh MW, Johnson R, Davis SD. Physiologic, bronchoscopic, and bronchoalveolar lavage fluid findings in young children with recurrent wheeze and cough. *Pediatric pulmonology* 2006;41:709-719.
20. Ullmann N, Sacco O, Gandullia P, Silvestri M, Pistorio A, Barabino A, Disma NM, Rossi GA. Usefulness and safety of double endoscopy in children with gastroesophageal reflux and respiratory symptoms. *Respir Med* 2010;104:593-599.
21. De Baets F, De Schutter I, Aarts C, Haerynck F, Van Daele S, De Wachter E, Malfroot A, Schelstraete P. Malacia, inflammation and bronchoalveolar lavage culture in children with persistent respiratory symptoms. *Eur Respir J* 2012;39:392-395.
22. Laberge J-M, Puligandla P. Congenital malformations of the lungs and airways. In: Landau LMTaLI, editor. *Pediatric respiratory medicine*, second edition, 2008 ed. Philadelphia: Mosby, Inc.; 2008. p. 907-942.
23. Davis S, Jones M, Kisling J, Angelicchio C, Tepper RS. Effect of continuous positive airway pressure on forced expiratory flows in infants with tracheomalacia. *American journal of respiratory and critical care medicine* 1998;158:148-152.
24. Wiseman NE, Duncan PG, Cameron CB. Management of tracheobronchomalacia with continuous positive airway pressure. *Journal of pediatric surgery* 1985;20:489-493.
25. Reiterer F, Eber E, Zach MS, Muller W. Management of severe congenital tracheobronchomalacia by continuous positive airway pressure and tidal breathing flow-volume loop analysis. *Pediatric pulmonology* 1994;17:401-403.
26. Pizer BL, Freeland AP, Wilkinson AR. Prolonged positive airway pressure for severe neonatal tracheobronchomalacia. *Archives of disease in childhood* 1986;61:908-909.

27. Miller RW, Pollack MM, Murphy TM, Fink RJ. Effectiveness of continuous positive airway pressure in the treatment of bronchomalacia in infants: A bronchoscopic documentation. *Critical care medicine* 1986;14:125-127.
28. Ferguson GT, Benoist J. Nasal continuous positive airway pressure in the treatment of tracheobronchomalacia. *The American review of respiratory disease* 1993;147:457-461.
29. Neijens HJ, Kerrebijn KF, Smalhout B. Successful treatment with cpap of two infants with bronchomalacia. *Acta paediatrica Scandinavica* 1978;67:293-296.
30. Panitch HB, Allen JL, Alpert BE, Schidlow DV. Effects of cpap on lung mechanics in infants with acquired tracheobronchomalacia. *American journal of respiratory and critical care medicine* 1994;150:1341-1346.
31. Blair GK, Cohen R, Filler RM. Treatment of tracheomalacia: Eight years' experience. *Journal of pediatric surgery* 1986;21:781-785.
32. Kamata S, Usui N, Sawai T, Nose K, Kitayama Y, Okuyama H, Okada A. Pexis of the great vessels for patients with tracheobronchomalacia in infancy. *Journal of pediatric surgery* 2000;35:454-457.
33. Greenholz SK, Karrer FM, Lilly JR. Contemporary surgery of tracheomalacia. *Journal of pediatric surgery* 1986;21:511-514.
34. Morabito A, MacKinnon E, Alizai N, Asero L, Bianchi A. The anterior mediastinal approach for management of tracheomalacia. *Journal of pediatric surgery* 2000;35:1456-1458.
35. Abdel-Rahman U, Ahrens P, Fieguth HG, Kitz R, Heller K, Moritz A. Surgical treatment of tracheomalacia by bronchoscopic monitored aortopexy in infants and children. *The Annals of thoracic surgery* 2002;74:315-319.
36. Bullard KM, Scott Adzick N, Harrison MR. A mediastinal window approach to aortopexy. *Journal of pediatric surgery* 1997;32:680-681.
37. Delgado MD, Matute JA, Jimenez MA, Aguado P, Benavent MI, Filler RM, Berchi FJ. [the treatment of the tracheobronchomalacia in pediatric age]. *Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica* 1997;10:65-69.
38. Tazuke Y, Kawahara H, Yagi M, Yoneda A, Soh H, Maeda K, Yamamoto T, Imura K. Use of a palmaz stent for tracheomalacia: Case report of an infant with esophageal atresia. *Journal of pediatric surgery* 1999;34:1291-1293.
39. Filler RM, Forte V, Chait P. Tracheobronchial stenting for the treatment of airway obstruction. *Journal of pediatric surgery* 1998;33:304-311.
40. Furman RH, Backer CL, Dunham ME, Donaldson J, Mavroudis C, Holinger LD. The use of balloon-expandable metallic stents in the treatment of pediatric tracheomalacia and bronchomalacia. *Archives of otolaryngology--head & neck surgery* 1999;125:203-207.
41. Casiano RR, Numa WA, Nurko YJ. Efficacy of transoral intraluminal wallstents for tracheal stenosis or tracheomalacia. *The Laryngoscope* 2000;110:1607-1612.
42. Tsugawa C, Nishijima E, Muraji T, Yoshimura M, Tsubota N, Asano H. A shape memory airway stent for tracheobronchomalacia in children: An experimental and clinical study. *Journal of pediatric surgery* 1997;32:50-53.
43. Bairdain S, Smithers CJ, Hamilton TE, Zurakowski D, Rhein L, Foker JE, Baird C, Jennings RW. Direct tracheobronchopexy to correct airway collapse due to severe

tracheobronchomalacia: Short-term outcomes in a series of 20 patients. *Journal of pediatric surgery* 2015;50:972-977.

44. Shah RK, Mora BN, Bacha E, Sena LM, Buonomo C, Del Nido P, Rahbar R. The presentation and management of vascular rings: An otolaryngology perspective. *International journal of pediatric otorhinolaryngology* 2007;71:57-62.
45. Greenhill ED, Skinner K. Impaired nursing students: An intervention program. *The Journal of nursing education* 1991;30:379-381.
46. Woods RK, Sharp RJ, Holcomb GW, 3rd, Snyder CL, Lofland GK, Ashcraft KW, Holder TM. Vascular anomalies and tracheoesophageal compression: A single institution's 25-year experience. *The Annals of thoracic surgery* 2001;72:434-438; discussion 438-439.
47. Koontz CS, Bhatia A, Forbess J, Wulkan ML. Video-assisted thoracoscopic division of vascular rings in pediatric patients. *The American surgeon* 2005;71:289-291.
48. Al-Bassam A, Saquib Mallick M, Al-Qahtani A, Al-Tokhais T, Gado A, Al-Boukai A, Thalag A, Alsaadi M. Thoracoscopic division of vascular rings in infants and children. *Journal of pediatric surgery* 2007;42:1357-1361.
49. Suematsu Y, Mora BN, Mihaljevic T, del Nido PJ. Totally endoscopic robotic-assisted repair of patent ductus arteriosus and vascular ring in children. *The Annals of thoracic surgery* 2005;80:2309-2313.
50. Kogon BE, Forbess JM, Wulkan ML, Kirshbom PM, Kanter KR. Video-assisted thoracoscopic surgery: Is it a superior technique for the division of vascular rings in children? *Congenital heart disease* 2007;2:130-133.
51. Panitch HB, Keklikian EN, Motley RA, Wolfson MR, Schidlow DV. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. *Pediatric pulmonology* 1990;9:170-176.
52. Rappaport BA, Suresh S, Hertz S, Evers AS, Orser BA. Anesthetic neurotoxicity--clinical implications of animal models. *N Engl J Med* 2015;372:796-797.
53. Schellhase DE, Fawcett DD, Schutze GE, Lensing SY, Tryka AF. Clinical utility of flexible bronchoscopy and bronchoalveolar lavage in young children with recurrent wheezing. *The Journal of pediatrics* 1998;132:312-318.
54. Marguet C, Jouen-Boedes F, Dean TP, Warner JO. Bronchoalveolar cell profiles in children with asthma, infantile wheeze, chronic cough, or cystic fibrosis. *American journal of respiratory and critical care medicine* 1999;159:1533-1540.
55. Fayon M, Just J, Thien HV, Chiba T, Pascual L, Sandouk G, Grimfeld A. Bacterial flora of the lower respiratory tract in children with bronchial asthma. *Acta paediatrica* 1999;88:1216-1222.
56. Marguet C, Dean TP, Warner JO. Soluble intercellular adhesion molecule-1 (sICAM-1) and interferon-gamma in bronchoalveolar lavage fluid from children with airway diseases. *American journal of respiratory and critical care medicine* 2000;162:1016-1022.
57. Krawiec ME, Westcott JY, Chu HW, Balzar S, Trudeau JB, Schwartz LB, Wenzel SE. Persistent wheezing in very young children is associated with lower respiratory inflammation. *American journal of respiratory and critical care medicine* 2001;163:1338-1343.

58. Arnoux B, Bousquet J, Rongier M, Scheinmann P, de Blic J. Increased bronchoalveolar lavage cd8 lymphocyte subset population in wheezy infants. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2001;12:194-200.
59. Nagayama Y, Tsubaki T, Toba T, Nakayama S, Kiyofumi O. Analysis of sputum taken from wheezy and asthmatic infants and children, with special reference to respiratory infections. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2001;12:318-326.
60. Chang AB, Cox NC, Faoagali J, Cleghorn GJ, Beem C, Ee LC, Withers GD, Patrick MK, Lewindon PJ. Cough and reflux esophagitis in children: Their co-existence and airway cellularity. *BMC pediatrics* 2006;6:4.
61. Maclellan C, Hutchinson P, Holdsworth S, Bardin PG, Freezer NJ. Airway inflammation in asymptomatic children with episodic wheeze. *Pediatric pulmonology* 2006;41:577-583.
62. Marchant JM, Masters IB, Taylor SM, Cox NC, Seymour GJ, Chang AB. Evaluation and outcome of young children with chronic cough. *Chest* 2006;129:1132-1141.
63. Donnelly D, Critchlow A, Everard ML. Outcomes in children treated for persistent bacterial bronchitis. *Thorax* 2007;62:80-84.
64. Byrnes C, Edwards E. Outcomes in children treated for persistent bacterial bronchitis. *Thorax* 2007;62:922-923; author reply 923.
65. Marchant JM, Gibson PG, Grissell TV, Timmins NL, Masters IB, Chang AB. Prospective assessment of protracted bacterial bronchitis: Airway inflammation and innate immune activation. *Pediatric pulmonology* 2008;43:1092-1099.
66. Khoshoo V, Edell D, Mohnot S, Haydel R, Jr., Saturno E, Kobernick A. Associated factors in children with chronic cough. *Chest* 2009;136:811-815.
67. Rosen R, Johnston N, Hart K, Khatwa U, Katz E, Nurko S. Higher rate of bronchoalveolar lavage culture positivity in children with nonacid reflux and respiratory disorders. *The Journal of pediatrics* 2011;159:504-506.
68. Zgherea D, Pagala S, Mendiratta M, Marcus MG, Shelov SP, Kazachkov M. Bronchoscopic findings in children with chronic wet cough. *Pediatrics* 2012;129:e364-369.
69. Kompare M, Weinberger M. Protracted bacterial bronchitis in young children: Association with airway malacia. *The Journal of pediatrics* 2012;160:88-92.
70. Chang AB, Redding GJ, Everard ML. Chronic wet cough: Protracted bronchitis, chronic suppurative lung disease and bronchiectasis. *Pediatric pulmonology* 2008;43:519-531.
71. Marchant J, Masters IB, Champion A, Petsky H, Chang AB. Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough. *Thorax* 2012;67:689-693.
72. Gibson MK, Crofts TS, Dantas G. Antibiotics and the developing infant gut microbiota and resistome. *Current opinion in microbiology* 2015;27:51-56.
73. Debley JS, Stamey DC, Cochrane ES, Gama KL, Redding GJ. Exhaled nitric oxide, lung function, and exacerbations in wheezy infants and toddlers. *J Allergy Clin Immunol* 2010;125:1228-1234 e1213.

74. Elliott M, Heltshe SL, Stamey DC, Cochrane ES, Redding GJ, Debley JS. Exhaled nitric oxide predicts persistence of wheezing, exacerbations, and decline in lung function in wheezy infants and toddlers. *Clin Exp Allergy* 2013;43:1351-1361.
75. Kurland G, Deterding RR, Hagood JS, Young LR, Brody AS, Castile RG, Dell S, Fan LL, Hamvas A, Hilman BC, Langston C, Noguee LM, Redding GJ, American Thoracic Society Committee on Childhood Interstitial Lung D, the ch ILDRN. An official american thoracic society clinical practice guideline: Classification, evaluation, and management of childhood interstitial lung disease in infancy. *American journal of respiratory and critical care medicine* 2013;188:376-394.
76. Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, Plaut M, Cooper SF, Fenton MJ, Arshad SH, Bahna SL, Beck LA, Byrd-Bredbenner C, Camargo CA, Jr., Eichenfield L, Furuta GT, Hanifin JM, Jones C, Kraft M, Levy BD, Lieberman P, Luccioli S, McCall KM, Schneider LC, Simon RA, Simons FE, Teach SJ, Yawn BP, Schwaninger JM. Guidelines for the diagnosis and management of food allergy in the united states: Summary of the niaid-sponsored expert panel report. *Nutrition research* 2011;31:61-75.
77. Miskelly FG, Burr ML, Vaughan-Williams E, Fehily AM, Butland BK, Merrett TG. Infant feeding and allergy. *Archives of disease in childhood* 1988;63:388-393.
78. Chan YH, Shek LP, Aw M, Quak SH, Lee BW. Use of hypoallergenic formula in the prevention of atopic disease among asian children. *J Paediatr Child Health* 2002;38:84-88.
79. Tromp, II, Kiefte-de Jong JC, Lebon A, Renders CM, Jaddoe VW, Hofman A, de Jongste JC, Moll HA. The introduction of allergenic foods and the development of reported wheezing and eczema in childhood: The generation r study. *Archives of pediatrics & adolescent medicine* 2011;165:933-938.
80. Burr ML, Limb ES, Maguire MJ, Amarah L, Eldridge BA, Layzell JC, Merrett TG. Infant feeding, wheezing, and allergy: A prospective study. *Archives of disease in childhood* 1993;68:724-728.
81. James JM, Bernhisel-Broadbent J, Sampson HA. Respiratory reactions provoked by double-blind food challenges in children. *American journal of respiratory and critical care medicine* 1994;149:59-64.
82. Buts JP, Barudi C, Moulin D, Claus D, Cornu G, Otte JB. Prevalence and treatment of silent gastro-oesophageal reflux in children with recurrent respiratory disorders. *Eur J Pediatr* 1986;145:396-400.
83. Yuksel H, Yilmaz O, Kirmaz C, Aydogdu S, Kasirga E. Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. *Respir Med* 2006;100:393-398.
84. Eid NS, Shepherd RW, Thomson MA. Persistent wheezing and gastroesophageal reflux in infants. *Pediatric pulmonology* 1994;18:39-44.
85. Berquist WE, Rachelefsky GS, Kadden M, Siegel SC, Katz RM, Fonkalsrud EW, Ament ME. Gastroesophageal reflux-associated recurrent pneumonia and chronic asthma in children. *Pediatrics* 1981;68:29-35.
86. Ghezzi M, Silvestri M, Guida E, Pistorio A, Sacco O, Mattioli G, Jasonni V, Rossi GA. Acid and weakly acid gastroesophageal refluxes and type of respiratory symptoms in children. *Respir Med* 2011;105:972-978.

87. Fohl AL, Regal RE. Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all? *World journal of gastrointestinal pharmacology and therapeutics* 2011;2:17-26.
88. Balson BM, Kravitz EK, McGeady SJ. Diagnosis and treatment of gastroesophageal reflux in children and adolescents with severe asthma. *Ann Allergy Asthma Immunol* 1998;81:159-164.
89. Arasu TS, Wyllie R, Fitzgerald JF, Franken EA, Siddiqui AR, Lehman GA, Eigen H, Grosfeld JL. Gastroesophageal reflux in infants and children comparative accuracy of diagnostic methods. *The Journal of pediatrics* 1980;96:798-803.
90. Patra S, Singh V, Chandra J, Kumar P, Tripathi M. Diagnostic modalities for gastro-esophageal reflux in infantile wheezers. *Journal of tropical pediatrics* 2011;57:99-103.
91. Karaman O, Uzuner N, Degirmenci B, Uguz A, Durak H. Results of the gastroesophageal reflux assessment in wheezy children. *Indian J Pediatr* 1999;66:351-355.
92. Thomas EJ, Kumar R, Dasan JB, Kabra SK, Bal CS, Menon S, Malhotra A. Gastroesophageal reflux in asthmatic children not responding to asthma medication: A scintigraphic study in 126 patients with correlation between scintigraphic and clinical findings of reflux. *Clinical imaging* 2003;27:333-336.
93. Mercado-Deane MG, Burton EM, Harlow SA, Glover AS, Deane DA, Guill MF, Hudson V. Swallowing dysfunction in infants less than 1 year of age. *Pediatr Radiol* 2001;31:423-428.
94. Sheikh S, Allen E, Shell R, Hruschak J, Iram D, Castile R, McCoy K. Chronic aspiration without gastroesophageal reflux as a cause of chronic respiratory symptoms in neurologically normal infants. *Chest* 2001;120:1190-1195.

ATS Wheezing Infants Online Supplement

TABLE OF CONTENTS

Methods

- Project history
- Committee composition
- Project scope
- Questions, outcomes, and literature search
- Evidence appraisal and recommendations
- Manuscript preparation

METHODS

Project history

The impetus for developing clinical practice guidelines about infantile wheezing came from an online survey of members of the Pediatric Assembly of the American Thoracic Society (ATS), where the topic was cited as one of the highest ranked topics for which members wanted guidelines developed. In response to the survey, one of the co-chairs (CLR) submitted an application to the Pediatric Assembly of the ATS to develop clinical practice guidelines. The proposal was reviewed by the Planning Committee of the Pediatric Assembly, the ATS Document Development and Implementation Committee, and the ATS Program Review Subcommittee before being approved and funded by the ATS Board of Directors.

Committee composition

Invitations to participate in the project were extended by the co-chairs (CLR, CE) to the membership of the ATS Pediatric Assembly. Interested individuals disclosed their potential conflicts of interest to the ATS and their disclosures were subsequently vetted according to the policies and procedures of the ATS. Those who qualified for participation were assigned to the task force. Task force members were assigned to specific sections of the document by the co-chairs.

Project scope

There are many diagnostic tests for infantile wheezing that are considered standard of care (e.g., chest radiography). The task force chose to not focus on these tests, but rather decided to address diagnostic approaches that are frequently considered by pediatric pulmonologists and other providers when caring for wheezing infants but are subject to uncertainty or controversy.

Questions, outcomes, and literature search

The task force met in person at the ATS International Conference and selected clinical questions that experienced clinicians frequently encounter in the evaluation of wheezing infants. The questions were then phrased in PICO (Patient, Intervention, Comparator, and Outcome) format. Patient-important outcomes were selected and prioritized. Frequency of wheezing was selected as a critical outcome. Frequency of doctor visits, frequency of hospitalization, prescriptions for bronchodilators, prescriptions for inhaled or systemic corticosteroids, parental stress, additional diagnostic testing, and inappropriate therapy were selected as important outcomes.

A pragmatic evidence synthesis was performed for each question. A medical librarian from the Miner Library at the University of Rochester generated search algorithms based upon key words provided by the task force and her own experience and then searched two electronic databases (Medline and CINAHL) using pre-specified search terms. The search results were divided among the task force members for selection of studies based upon pre-specified selection criteria. Task force members were encouraged to supplement the search results with relevant articles that may not have been detected through the electronic search.

The task force initially sought randomized trials or controlled observational studies that compared the effect of different approaches on clinically important outcomes. Accuracy studies were sought if no controlled studies were identified and the diagnostic intervention was not the gold

standard; prevalence studies were sought if no controlled studies were identified and the diagnostic intervention was the gold standard.

Evidence appraisal and recommendations

For each outcome, the evidence was summarized and the quality of evidence appraised using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach, which categorizes the quality of evidence as high, moderate, low, or very low [1]. The guideline development committee then used the evidence synthesis as the basis for its recommendations. The committee formulated recommendations by considering the balance of benefits versus harms and burdens, quality of evidence, patient/family values and preferences, and resource use [2]. Consensus was achieved through discussion at in person meetings, teleconferences, and emails.

A strong recommendation indicates that the task force is certain that the desirable consequences of an intervention (i.e., benefits) will outweigh the undesirable consequences (i.e., harms, burdens, costs) [2]. A conditional recommendation indicates that there is uncertainty that the desirable consequences outweigh the undesirable consequences [2]. In other words, a conditional recommendation is the right thing to do for most patients, but may not be right for a sizable minority of patients depending upon the clinical context. Conditional recommendations are most common when the quality of evidence is low or very low, or the potential desirable and undesirable consequences are finely balanced. A research recommendation was made if there was not enough evidence to render a meaningful recommendation or if the committee could not reach a consensus on the recommendation.

Manuscript preparation

For each clinical question, an author summarized the evidence that was used by the committee to inform the related recommendation, provided the committee's rationale for the recommendation,

and then stated the final graded recommendation. The author then submitted the content to the co-chairs, who combined the sections into a single document. The draft document then went through multiple iterative cycles of review and revisions. The final document was reviewed and approved by all committee members before being submitted for peer review. Following multiple cycles of external peer review and revisions, the guidelines were reviewed and approved by the ATS Board of Directors.

REFERENCES

1. Guyatt G, Akl EA, Oxman A, Wilson KC, Puhan MA, Wilt T, Gutterman D, Woodhead M, Antman EM, and Schunemann HJ. Synthesis, Grading, and Presentation of Evidence in Guidelines: Article 7 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. *Proc Am Thorac Soc* 2012; 9(5):256-261.
2. Schunemann HJ, Oxman AD, Akl EA, Brozek JL, Montori VM, Heffner J, Hill S, Woodhead M, Campos-Outcalt D, Alderson P, et al. Moving from Evidence to Developing Recommendations in Guidelines: Article 11 in Integrating and Coordinating Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. *Proc Am Thorac Soc* 2012; 9(5):282-292.